John H. Barton - Concepedia

Concepedia

Author

John H. Barton

Tennessee Oncology

Also Known As

J Barton, J. Barton, J. H. Barton, John Barton, John H. Barton, Jude Barton

38

Publications

1.1K

Citations

15

H-Index

30

Concepts

All Affiliations

Tennessee Oncology Sarah Cannon Florida Cancer Specialists & Research Institute

JH

About

John H. Barton is an author at Tennessee Oncology specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	363
2	Health Sciences	6	6	129
3	Cell Biology	1	1	27
4	Diagnostic Sciences	1	1	15
5	Immunology	1	1	27

John H. Barton

×

20

Publications

1.1K

Citations

15

H-Index

	Year	Citations
Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network John D. Hainsworth, Sharlene Litchy, John H. Barton, Journal of Clinical Oncology	2003	350
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma John D. Hainsworth, Howard A. Burris, Sharlene Litchy, Cancer	2000	140
Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study F. Anthony Greco, Howard A. Burris, Sharlene Litchy, Journal of Clinical Oncology	2002	111
Weekly Docetaxel and Bortezomib as First-Line Treatment for Patients with Hormone-Refractory Prostate Cancer: A Minnie Pearl Cancer Research Network Phase II Trial John D. Hainsworth, Anthony A. Meluch, David R. Spigel, Clinical Genitourinary Cancer UrologyGenitourinary CancerMedicineWeekly DocetaxelFirst-line Treatment	2007	51
A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer Denise A. Yardley, Howard A. Burris, Lisa Simons, Clinical Breast Cancer Metastatic Breast CancerBreast OncologyPhase Ii TrialMedicinePharmacology	2008	43
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer Johanna C. Bendell, Suzanne F. Jones, Lowell L. Hart, Investigational New Drugs Phase Ib StudyDual InhibitorIr Tyrosine KinaseOncologyGastrointestinal Oncology	2014	42
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma F. Anthony Greco, James R. Gray, Dana S. Thompson, Cancer Median SurvivalMedicineCancer ManagementChemotherapyBronchial Neoplasm	2002	40
Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium Denise A. Yardley, Howard A. Burris, Bobby L. Clark, Clinical Breast Cancer Breast OncologyPhase Ii TrialMedicineGynecologyBreast Cancer	2011	33
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma John D. Hainsworth, David R. Spigel, John H. Barton, Cancer	2008	32
Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site John D. Hainsworth, David R. Spigel, Howard A. Burris, Cancer	2010	27

Page 1